Dr. Gregg Day talks with Dr. Avi Nath, Clinical Director of the National Institute of Neurological Disorders and Stroke (NINDS), about COVID brain fog and other cognitive syndromes. Read the full article referenced in this podcast in the Washington Post.

Dr. Justin Abbatemarco talks with Prof. Sarosh Irani about the use of corticosteroids as a first-line agent in the treatment of LGI1 antibody encephalitis.

Dr. Gregg Day talks with Dr. Walter Koroshetz, Director of the National Institute of Neurological Disorders and Stroke, about NINDS's mission and clinical neurology.

Dr. Jeff Burns talks with Dr. Ron Petersen, Director of the Mayo Clinic Alzheimer's Disease Research Center, about Medicare's recent decision to officially limit Aduhelm (aducanumab) coverage to patients in clinical trials. Read the full article discussed in this interview in the New York Times.

Dr. Karen Hirsch talks with Dr. Linnéa Grindegård about the association between EEG patterns and serum neurofilament light as a marker of neuroaxonal injury after cardiac arrest. Read the full article in Neurology.

Drs. B.J. Hicks and Andy Southerland talk with Dr. Scott Mendelson about racial and ethnic disparities in the rates of declination of thrombolysis in patients with acute ischemic stroke. Read the full article in Neurology.

Dr. Justin Abbatemarco talks with Prof. Gráinne Gorman about the use of L-arginine in the treatment of mitochondrial encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Read the full article in Neurology.

Dr. Fábio Nascimento talks with Dr. Elaine Pang about the identification and characterization of pure sleep epilepsy after first-ever seizures from sleep in adults. Read the full article in Neurology.

The June 2022 replay of past episodes showcases a selection of interviews about the impact of the FDA's approval of aducanumab for the treatment of Alzheimer disease (AD). This episode features illuminating conversations with Drs. Gregg Day, Ron Petersen, and Jason Karlawish on the clinical science guiding amyloid-based treatments for AD, the importance of patient participation when considering the use of aducanumab, and the business of Alzheimer disease, respectively. This month's Recall concludes with an interview featuring Pulitzer Prize-winning journalist Pam Belluck on Medicare's limitations on aducanumab coverage.

Dr. Jeff Ratliff talks with Dr. Meredith Bock about the association of motor, non-motor, and behavioral symptoms with health-related quality of life in people with Parkinson disease. Read the full article in Neurology.